
Conmed Corporation (($CNMD)) has held its Q3 earnings call. Read on for the main highlights of the call. ConMed’s latest earnings call struck a broadly upbeat tone despite a few
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CNMD | Conmed | 46.56 | 3.78 | 8.84% |
| Name | Price | % Change | |
|---|---|---|---|
| $46.56 | +8.84% |

Conmed Corporation (($CNMD)) has held its Q3 earnings call. Read on for the main highlights of the call. ConMed’s latest earnings call struck a broadly upbeat tone despite a few

JPMorgan raised the firm’s price target on Conmed (CNMD) to $50 from $45 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

Reports Q3 revenue $335.6M, consensus $336.3M. “Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team’s

Narrows FY26 revenue view to $1.36B-$1.366B from $1.358B-$1.373B Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks

Conmed Corporation (CNMD) is scheduled to report 3rd quarter earnings on 10/28/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Conmed Corporation to post earnings of $1.00

Avantor (AVTR) appoints Todd Garner as EVP and CFO. Garner will oversee the company’s global finance organization, including financial planning and analysis, accounting, treasury, tax, investor relations and internal audit.

Conmed Corporation (($CNMD)) has held its Q2 earnings call. Read on for the main highlights of the call. Conmed’s latest earnings call struck a cautiously upbeat tone, with management highlighting

JPMorgan raised the firm’s price target on Conmed (CNMD) to $45 from $40 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Conmed (CNMD) to $45 from $39 and keeps a Neutral rating on the shares. The firm notes the company

Needham analyst Michael Matson has maintained their neutral stance on CNMD stock, giving a Hold rating on July 13. Michael Matson has given his Hold rating due to a combination
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 3, 2027TBA | $1.38B | $1.26 | $366.55M | -0.41 | 19.24 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.